126 related articles for article (PubMed ID: 9842923)
21. Leishmania major: targeting IL-4 in successful immunomodulation of murine infection.
Wakil AE; Wang ZE; Locksley RM
Exp Parasitol; 1996 Nov; 84(2):214-22. PubMed ID: 8932771
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasis.
Moll H; Berberich C
Immunobiology; 2001 Dec; 204(5):659-66. PubMed ID: 11846231
[TBL] [Abstract][Full Text] [Related]
23. Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major.
Doherty TM; Coffman RL
J Immunol; 1993 Jun; 150(12):5476-83. PubMed ID: 8515072
[TBL] [Abstract][Full Text] [Related]
24. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells in Leishmania major-immune mice harbor persistent parasites and mediate an antigen-specific T cell immune response.
Moll H; Flohé S; Röllinghoff M
Eur J Immunol; 1995 Mar; 25(3):693-9. PubMed ID: 7705398
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
[TBL] [Abstract][Full Text] [Related]
27. Antigen presentation by epidermal Langerhans cells in experimental cutaneous leishmaniasis.
Axelrod O; Klaus S; Frankenburg S
Parasite Immunol; 1994 Nov; 16(11):593-8. PubMed ID: 7862465
[TBL] [Abstract][Full Text] [Related]
28. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
Tonui WK; Titus RG
Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
[TBL] [Abstract][Full Text] [Related]
29. IL-12 is required to maintain a Th1 response during Leishmania major infection.
Park AY; Hondowicz BD; Scott P
J Immunol; 2000 Jul; 165(2):896-902. PubMed ID: 10878364
[TBL] [Abstract][Full Text] [Related]
30. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.
Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G
Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560
[TBL] [Abstract][Full Text] [Related]
31. Post challenging serum cytokine profile (Th1 & Th2) in the vaccinated mice (Balb/C) with a new formulation of Leishmania major antigen.
Latifynia A; Khamisipour A; Gharagozlou MJ; Bokaie S; Vodjgani M; Gheflati Z; Mosavi M; Khansari N
Turkiye Parazitol Derg; 2013; 37(4):233-40. PubMed ID: 24412861
[TBL] [Abstract][Full Text] [Related]
32. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.
Eskandari F; Talesh GA; Parooie M; Jaafari MR; Khamesipour A; Saberi Z; Abbasi A; Badiee A
Exp Parasitol; 2014 Nov; 146():78-86. PubMed ID: 25246326
[TBL] [Abstract][Full Text] [Related]
33. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages.
Shimizu Y; Takagi H; Nakayama T; Yamakami K; Tadakuma T; Yokoyama N; Kojima N
Parasite Immunol; 2007 May; 29(5):229-39. PubMed ID: 17430546
[TBL] [Abstract][Full Text] [Related]
34. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-).
Xu D; McSorley SJ; Chatfield SN; Dougan G; Liew FY
Immunology; 1995 May; 85(1):1-7. PubMed ID: 7635511
[TBL] [Abstract][Full Text] [Related]
35. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
[TBL] [Abstract][Full Text] [Related]
36. T cells that react to the immunodominant Leishmania major LACK antigen prevent early dissemination of the parasite in susceptible BALB/c mice.
Schilling S; Glaichenhaus N
Infect Immun; 2001 Feb; 69(2):1212-4. PubMed ID: 11160025
[TBL] [Abstract][Full Text] [Related]
37. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.
Al-Wabel MA; Tonui WK; Cui L; Martin SK; Titus RG
Am J Trop Med Hyg; 2007 Dec; 77(6):1060-5. PubMed ID: 18165522
[TBL] [Abstract][Full Text] [Related]
38. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
Scharton-Kersten T; Afonso LC; Wysocka M; Trinchieri G; Scott P
J Immunol; 1995 May; 154(10):5320-30. PubMed ID: 7730635
[TBL] [Abstract][Full Text] [Related]
39. Expression cloning of a protective Leishmania antigen.
Mougneau E; Altare F; Wakil AE; Zheng S; Coppola T; Wang ZE; Waldmann R; Locksley RM; Glaichenhaus N
Science; 1995 Apr; 268(5210):563-6. PubMed ID: 7725103
[TBL] [Abstract][Full Text] [Related]
40. Leishmania major infection in major histocompatibility complex class II-deficient mice: CD8+ T cells do not mediate a protective immune response.
Erb K; Blank C; Ritter U; Bluethmann H; Moll H
Immunobiology; 1996 Jul; 195(2):243-60. PubMed ID: 8877400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
